Acotiamide

Source: Wikipedia, the free encyclopedia.
Acotiamide
Clinical data
Trade namesAcofide
Other namesYM-443, Z-338
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • JP: Rx-only
Pharmacokinetic data
Protein binding84.21–85.95%
MetabolismUGT1A8 and 1A9 (major)
Elimination half-life10.9–21.7 hours
ExcretionFeces (92.7%), urine (5.3%)[1]
Identifiers
  • N-{2-[bis(1-Methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide
JSmol)
  • O=C(Nc1nc(C(=O)NCCN(C(C)C)C(C)C)cs1)c2cc(OC)c(OC)cc2O
  • InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27) checkY
  • Key:TWHZNAUBXFZMCA-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Acotiamide, sold under the brand name Acofide,

postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.[4] It acts as an acetylcholinesterase inhibitor
.

References

  1. ^ "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
  2. S2CID 20383853
    .
  3. PMID 24531902
    .
  4. S2CID 41298446
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Acotiamide&oldid=1179439636"